Drug Trial Radar · NCT02669511
PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
Last checked: Nov 19, 2026Latest source record: Jul 9, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21
Actual
Start
Nov 12, 2015
Primary completion
Jan 12, 2018
Study completion Jan 12, 2018
Sponsor
- Lead sponsor
- PIQUR Therapeutics AGIndustry
- Sponsor type
- Industry
- First posted
- Feb 1, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label, non-randomized, two-stage, multicenter study evaluating clinical efficacy, safety and pharmacokinetics of PQR309 in patients with relapsed or refractory Primary Central Nervous System Lymphoma (PCNSL).
Conditions
- Primary Central Nervous System Lymphoma
Interventions
PQR309Drug
Oral PQR309, 80mg or 60mg daily or intermittent dosing
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR)Time frame: Every 8 weeks up to 6 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.